See Special Populations, Immunocompromised Patients for more information. *The recommended duration in immunocompromised patients (≥1 year old) is 10 days. The following weight-adjusted dosing regimens are recommended for infants and children 1 year of age or older: Tamiflu 30 mg and 45 mg capsules are available as an alternative to the recommended dose of Tamiflu 6 mg/ml suspension. Treatment should be initiated as soon as possible within the first two days of onset of symptoms of influenza.įor adolescents (13 to 17 years of age) and adults: The recommended oral dose is 75 mg oseltamivir twice daily for 5 days (or 10 days in immunocompromised patients).įor infants and children1 year of age or older: The recommended dose of Tamiflu 6 mg/ml oral suspension is indicated in the table below.
#45 meg persecond vs 95 meg persecond plus
by administering one 30 mg dose plus one 45 mg dose of suspension.Īdults, adolescents or children (> 40 kg) who are able to swallow capsules may receive appropriate doses of Tamiflu capsules. one 30 mg capsule plus one 45 mg capsule or 75 mg doses can be administered as either Tamiflu suspension and Tamiflu hard capsules are bioequivalent formulations. Decisions regarding the use of oseltamivir for treatment and prophylaxis should take into consideration what is known about the characteristics of the circulating influenza viruses, available information on influenza drug susceptibility patterns for each season and the impact of the disease in different geographical areas and patient populations (see section 5.1). The use of antivirals for the treatment and prevention of influenza should be determined on the basis of official recommendations. Tamiflu is not a substitute for influenza vaccination. Tamiflu is indicated for post-exposure prevention of influenza in infants less than 1 year of age during a pandemic influenza outbreak (see section 5.2). in case of a mismatch between the circulating and vaccine virus strains, and a pandemic situation) seasonal prevention could be considered in individuals one year of age or older. The appropriate use of Tamiflu for prevention of influenza should be determined on a case by case basis by the circumstances and the population requiring protection. Post-exposure prevention in individuals 1 year of age or older following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community. Efficacy has been demonstrated when treatment is initiated within two days of first onset of symptoms.
#45 meg persecond vs 95 meg persecond full
Tamiflu is indicated in adults and children including full term neonates who present with symptoms typical of influenza, when influenza virus is circulating in the community. Date of first authorisation/renewal of the authorisation 6.6 Special precautions for disposal and other handling.4.7 Effects on ability to drive and use machines.4.5 Interaction with other medicinal products and other forms of interaction.4.4 Special warnings and precautions for use.4.2 Posology and method of administration.Show table of contents Hide table of contents
0 kommentar(er)
